International Journal of STD & AIDS > Volume 20, Number 2 > Pp. 138-139

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Deko, O A Articles by Jaleel, H Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Audit reports

Long-term suppressive therapy for herpes simplex – an audit

O A Deko MBBS, A Pakozdi MD, D T P Evans FRCP FRACP  and H Jaleel MRCOG MSc

Department of Genito-Urinary Medicine, Southend University Hospital NHS Foundation Trust, Prittlewell Chase, WestCliff-on-Sea, Essex SS0 0RY, UK

Correspondence to: Derek T P Evans Email: Derek.evans{at}southend.nhs.uk

A retrospective analysis of patients, who have been on long-term suppressive therapy for recurrent episodes of herpes simplex (HSV) in a university hospital, was performed and the findings were documented and orchestrated into bar graphs. The study involved patients between the years 2000 and 2007, both inclusive. The results were compared with the British Association for Sexual Health and HIV guidelines. Eighty-two percent (57) had had the infection for at least 12 months at the start of therapy and 78.2% (54) had at least six recurrences per year before the start of treatment. Indeed, only four patients (5.8%) had a treatment interruption at 12 months or less; also only 11 patients (15.9%) had less than six outbreaks per year at the start of treatment. The former is not in-line and the latter is in-line with the guidelines.

Key Words: HSV (herpes simplex virus) • antiviral • treatment • prevention

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?